Cargando…

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans

Gefapixant (MK‐7264) is a first‐in‐class, selective antagonist of the P2X3 purinergic receptor currently being investigated as a therapeutic agent for the treatment of refractory or unexplained chronic cough. In non‐clinical studies, gefapixant was eliminated primarily by renal excretion of the pare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nussbaum, Jesse C., Hussain, Azher, Ma, Bennett, Min, K. Chris, Chen, Qing, Tomek, Charles, Iwamoto, Marian, Stoch, S. Aubrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929362/ https://www.ncbi.nlm.nih.gov/pubmed/35106949 http://dx.doi.org/10.1002/prp2.924

Ejemplares similares

Clinical Formulation Bridging of Gefapixant, a P2X3‐Receptor Antagonist, for the Treatment of Chronic Cough
por: Gupta, Pranav, et al.
Publicado: (2022)

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin
por: McCrea, Jacqueline B., et al.
Publicado: (2021)

Population pharmacokinetic analysis of the P2X3‐receptor antagonist gefapixant
por: Chawla, Akshita, et al.
Publicado: (2023)

A Phase 1 Trial to Evaluate the Relationship Between Fluoride Intake and Urinary Fluoride Excretion in Healthy Participants
por: Gillespie, Gillian, et al.
Publicado: (2021)

A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV
por: Matthews, Randolph P., et al.
Publicado: (2021)

Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor
por: Gillespie, Gillian, et al.
Publicado: (2021)

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
por: Ankrom, Wendy, et al.
Publicado: (2021)

546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
por: Matthews, Randolph, et al.
Publicado: (2018)

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans
por: Ong, Voon, et al.
Publicado: (2022)

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks
por: Birring, Surinder S., et al.
Publicado: (2023)

Absorption and Excretion of Antipyrine
Publicado: (1888)

Absorption, distribution, metabolism and excretion of molidustat in healthy participants
por: Lentini, Silvia, et al.
Publicado: (2020)

Absorption, metabolism and excretion of opicapone in human healthy volunteers
por: Loureiro, Ana I., et al.
Publicado: (2022)

1400. Mass Balance, Metabolism, and Excretion of [(14)C]-Plazomicin in Healthy Human Subjects
por: Choi, Taylor, et al.
Publicado: (2018)

Absorption, distribution, metabolism, and excretion of [(14)C]‐dasotraline in humans
por: Chen, Yu‐Luan, et al.
Publicado: (2016)

Lycopene: A Critical Review of Digestion, Absorption, Metabolism, and Excretion
por: Arballo, Joseph, et al.
Publicado: (2021)

Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials
por: Chuang, Min-Hsiang, et al.
Publicado: (2023)

Efficacy of Gefapixant, a P2X(3) Antagonist, for Refractory Atopic Cough
por: Ishiura, Yoshihisa, et al.
Publicado: (2023)

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
por: Muccino, David R., et al.
Publicado: (2020)

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions
por: Khalilieh, Sauzanne, et al.
Publicado: (2020)

Absorption, metabolism, and excretion of di(2-ethylhexyl) phthalate by rats and mice.
por: Albro, P W
Publicado: (1986)

Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats
por: Füll, Yvonne, et al.
Publicado: (2022)

A mass-balance approach to evaluate arsenic intake and excretion in different populations
por: Beene, Daniel, et al.
Publicado: (2022)

P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough
por: Cui, Wen-Wen, et al.
Publicado: (2022)

Metabolism, Excretion, and Pharmacokinetics of [(14)C]‐Cefiderocol (S‐649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration
por: Miyazaki, Shiro, et al.
Publicado: (2019)

The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2023)

Absorption, metabolism and excretion of [(14)C]pomalidomide in humans following oral administration
por: Hoffmann, Matthew, et al.
Publicado: (2012)

Absorption, distribution, metabolism, and excretion of [(14)C]-labeled naloxegol in healthy subjects
por: Bui, Khanh, et al.
Publicado: (2015)

Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan
por: Iskakova, Aisha N., et al.
Publicado: (2016)

Absorption, metabolism, excretion, and safety of [(14)C]almonertinib in healthy Chinese subjects
por: Zhou, Chen, et al.
Publicado: (2021)

Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
por: Smith, Jaclyn A., et al.
Publicado: (2022)

Diet in Disease: X.—Digestion—Absorption—Excretion
por: Hart, Ernest
Publicado: (1892)

An Investigation of the Metabolism and Excretion of KD101 and Its Interindividual Differences: A Microtracing Mass Balance Study in Humans
por: Kim, Anhye, et al.
Publicado: (2020)

Pharmacokinetics, Mass Balance, Excretion, and Tissue Distribution of Plasmalogen Precursor PPI-1011
por: Smith, Tara, et al.
Publicado: (2022)

Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats
por: Woodburn, Kathryn W., et al.
Publicado: (2011)

Observations on the Absorption, Excretion, Diffusion, and Acetylation of Sulfadiazine in Man
por: Sadusk, Joseph F., et al.
Publicado: (1941)

Observations on the Absorption, Excretion, Diffusion, and Acetylation of Sulfathiazole in Man
por: Sadusk, Joseph F., et al.
Publicado: (1940)

Efficacy of gefapixant, a P2X(3) antagonist, for lung cancer-related cough: a case report
por: Ishiura, Yoshihisa, et al.
Publicado: (2023)

Investigation of in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetics of paromomycin: Influence on oral bioavailability
por: K. Pinjari, M. Jakir S., et al.
Publicado: (2017)

Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents
por: Ohtsu, Yoshiaki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lhdht0n8irm7q3d2v0bslqld9q